Emerging Treatment Strategies for Advanced Cholangiocarcinoma 

This in-depth discussion, presented by Lipika Goyle, MD, Massachusetts General Hospital, will feature expert insights on emerging therapeutic treatments, recent discoveries on novel therapies, managing strategies for monitoring and managing adverse events, and much more! Start the activity now! STATEMENT OF NEED Cholangiocarcinoma, also known as bile duct cancer, is a rare malignancy originating in the epithelium of the bile duct. Accounting for only 3% of gastrointestinal tumors, it is ...
i3 Health

Video Viewpoint Strategy Session: Advances in the Treatment of Relapsed/Refractory Immune Thrombocytopenia

Learn new advances in the treatment of relapsed or refractory immune thrombocytopenia, including treatment differentiation, efficacy and safety strategies, and much more. This activity features perspectives from two noted experts in the field, Dr. Keith McCrae, Director of Benign Hematology at the Cleveland Clinic Taussig Cancer Center; and Ms. Phyllis McKiernan, Advanced Practice Nurse in Blood & Marrow Stem Cell Transplantation at the John Theurer Cancer Center, Hackensack Meridian Health. ...
i3 Health

Oncology Nursing Showdown! Aggressive Non–Hodgkin Lymphoma Edition: Module 3 - Peripheral T-Cell Lymphoma

In the third segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD, Anderson Cancer Center, evaluates guideline recommendations for the management of peripheral T-cell lymphoma (PTCL), assesses emerging data on novel therapies, and applies strategies to optimize treatment experiences for patients. For more expert insights on aggressive non-hodgkin lymphoma, complete modules 2 and 3. Start the activity now! Each year, 81,560 new cases of non-Hod...
i3 Health

Oncology Nursing Showdown! Aggressive Non–Hodgkin Lymphoma Edition: Module 2 - Mantel Cell Lymphoma

In the second segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD Anderson Cancer Center, shares expert insights on guideline recommendations for optimizing individual patient care, efficacy and safety data, and strategies to manage adverse event for patients with advanced aggressive mantle cell lymphoma (MCL). For more expert insights on aggressive non-Hodgkin lymphoma, complete modules 1 and 3. Start the activity now! Each year, 81,560 new c...
i3 Health

Oncology Nursing Showdown! Aggressive Non–Hodgkin Lymphoma Edition: Module 1 - Diffuse Large B-Cell Lymphoma

In the first segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD Anderson Cancer Center, evaluates guideline recommendations for the management of patients with advanced diffuse large B-cell lymphoma (DLBCL). Learners will receive expert insight on assessing emerging data on novel therapies, strategies to manage adverse events, and optimizing treatment for patients with advanced DLBCL. Complete modules 2 and 3 for more in-depth knowledge of ag...
i3 Health

Enhancing the Clinical Outcomes of Patients with Extensive–Stage Small Cell Lung Cancer

Join Anne Chiang, MD, PhD, Yale School of Medicine, a leading expert on small cell lung cancer, for an in-depth presentation on patient outcomes in extensive-small cell lung cancer. Dr. Chiang will present evidence-based advice regarding emerging therapies, strategies for targeted treatments and immunotherapy, optimization of individual patient treatment plans, managing adverse events, and much more! Don't miss this event! Register now! An estimated 228,820 new cases of lung cancer are repo...
i3 Health

New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertion–NSCLC

Discover new developments in the diagnosis and treatment of EGFR exon-20 Insertion–Mutant NSCLC and assess emerging efficacy and safety data on novel targeted therapies. This activity features expert insights from Helena Yu, MD, Memorial Sloan Kettering Cancer Center, and Maria Arcila, MD, Memorial Sloan Kettering Cancer Center. This activity is also available as a podcast. An estimated 235,760 new cases of lung cancer are reported in the United States annually, and 131,880 people die...
i3 Health

Current and Emerging Therapies for Lysosomal Storage Disease

This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available for other attendees.
CheckRare

An Interactive Guide to the Underdiagnosed, Underestimated, but Treatable Metabolic Disorders

This infographic activity uses a self-directed, visual update to the state-of-the-art diagnosis and management of treatable lysosomal storage disorders. Much of what you learned in your primary training may be outdated because of rapid advances in genetic, molecular, and clinical approaches to these conditions. While the LSDs were often fatal conditions, new treatments have completely changed the possible outcomes for patients, but a major barrier is recognition of the condition in time for tr...
Annenberg Center for Health Sciences at Eisenhower

New Opportunities in Advanced KRAS Mutation-Positive NSCLC

In this CME/NCPD activity, D. Ross Camidge, MD, PhD, of the University of Colorado, and Beth Sandy, MSN, CRNP, OCN®, of the University of Pennsylvania, discuss novel treatments for advanced KRAS mutation-positive NSCLC and how to manage adverse events associated with small molecule inhibitors. Start now!  An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 84% of cases are classified as...
i3 Health

Fabry Disease Research Highlights

At WORLDSymposium 2021, new information and data were presented on Fabry disease, a rare lysosomal storage disorder. This CME activity highlights the latest information about Fabry disease from WORLDSymposium 2021 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare condition.
CheckRare

Gaucher Disease Research Highlights: ASH 2020

At the American Society of Hematology Annual Meeting (ASH 2020), new information and data were presented on Gaucher disease, a rare lysosomal storage disorder, that requires a team of health care professionals to properly manage. This CME activity highlights the latest information about Gaucher disease from ASH 2020 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare condition. Activity Faculty
CheckRare

Meeting the Challenges in Management of Sickle Cell Disease

No longer a life-threatening disease, sickle cell disease (SCD) has become a chronic disease with life-threatening events that requires coordinated care by a multidisciplinary care team. Join Michael R. DeBaun, MD, MPH, and Collin Montgomery, APRN, as they discuss the acute and chronic complications experienced by individuals with SCD and the barriers they often encounter. The faculty offer real-world strategies for overcoming these barriers to improve the quality of life and other health outc...
Annenberg Center for Health Sciences at Eisenhower

Update on Therapeutic Advances in T-Cell Lymphoma

Join Steven M. Horwitz, MD, Member and Attending Physician at Memorial Sloan Kettering Cancer Center, as he discusses guideline recommendations for differential diagnosis of TCL, novel treatment strategies, and best practices for managing side effects in this case-based CME/NCPD activity! STATEMENT OF NEED Each year, 74,240 new cases of non-Hodgkin lymphoma are diagnosed and 19,940 people die of the disease (ACS, 2020). Among these cases, 12% to 15% are classified as peripheral T-cell l...
i3 Health

Optimizing the Management of Moderate-to-Severe Atopic Dermatitis in Adult Patients

STATEMENT OF NEED Atopic dermatitis is a severe form of eczema pathologically characterized by skin barrier disruption mediated by a type 2 helper T-cell immune response. The incidence of atopic dermatitis is high, estimated to be approximately 15% to 20% in children and 1% to 3% in adults worldwide (Avena-Woods, 2017). In addition to the hallmark clinical symptoms of eczema and intense pruritus, atopic dermatitis is associated with a substantial and multifaceted patient-reported burden tha...
i3 Health

Expert Updates in COVID19: An Animated Video Series

Five animated videos clearly explain managing patients with COVID19, lung disease, ARDS, or long-COVID. Hear from the leading pulmonologists on best practices based on the latest literature.
The France Foundation

Assessing a Patient With Long COVID-19: An Interactive Case Scenario

In this interactive case, the physician recommends a series of assessments for your patient with Long-COVID symptoms. For each assessment, the user chooses the outcome to hear recommendations from the experts.
The France Foundation

TEAM UP: Defining and Refining Optimal HIV Care During the COVID-19 Pandemic

In this webcast series, members of the DAP Health team review key data and discuss their real-world experiences providing care for persons living with HIV during the COVID-19 pandemic. DAP Health opened one of California’s first COVID-19 clinics and hotlines to offer screening, testing, and treatment. Topics covered in this webcast series include: COVID-19–Related Complications in Persons Living With HIV (PLWH); COVID-19 Testing Strategies; Home Care for PLWH Diagnosed With COVID-1...
Annenberg Center for Health Sciences at Eisenhower

Eye on Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease often characterized by sporadic and repeated inflammatory flare ups that can impact the optic nerve and/or spinal cord. With each repeated attack, additional permanent neurological damage will accrue. This CME activity highlights the important role both ophthalmologists and neurologists play in diagnosing and treating NMOSD most efficiently.
CheckRare

Pulmonary Arterial Hypertension (PAH) Highlights from CHEST 2020

Although CHEST 2020 was not a live, in-person meeting, new information and data regarding pulmonary arterial hypertension (PAH) will still be published but will not be easily accessible to the care team involved in the diagnosis and management of patients with this rare disease who need to know and incorporate the latest information into patient care. This CME activity highlights the latest research on PAH to help clinicians keep up to date on the most efficient ways to manage their patients.
CheckRare

Understanding Evolving Therapeutic Strategies for Graft-Versus-Host Disease (Module 1: Diagnosis, Risk Assessment, and Staging; Module 2: Current and Emerging Therapeutic Strategies)

STATEMENT OF NEED Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients and accounting for 15% of posttransplant mortality. Acute GVHD is the second-leading cause of transplant-related mortality and typically targets the skin, gastrointestinal tract, and liver. Chronic GVHD often presents during the first year following HSCT but may develop in subsequent years and most commonly affects the ...
i3 Health

Optimal Prehospital Management of Seizure Emergencies

In this program, the faculty will review and provide updates on the guidelines for managing seizure emergencies and address how participants can reduce the barriers to prehospital treatment through the use of Seizure Action Plans. They also will discuss recent clinical trials that may improve caregiver acceptance of rescue medications for status epilepticus. In addition, the faculty will address the similarities and differences in managing seizure emergencies for pediatric and adult patients.
Annenberg Center for Health Sciences at Eisenhower

Research Updates in Gout: Improving Response Rate to Therapy

Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practi...
Annenberg Center for Health Sciences at Eisenhower

A Case-Based Roadmap for Improved Patient Outcomes in Psoriatic Arthritis

Patients with psoriatic arthritis (PsA) experience significant disease burden due to incomplete diagnostic evaluation and suboptimal use of effective therapies. In this case-based activity, Dr. Leonard Calabrese of the Cleveland Clinic addressing these practice gaps by sharing his recommendations for patient management at critical decision points in the diagnosis and treatment of patients with PsA. Dr. Calabrese also discusses the important role of shared decision-making over the course of the...
Annenberg Center for Health Sciences at Eisenhower

Immunotherapy Advances in RRMM: An Educational Journey

Multiple myeloma has become the most common hematologic malignancy in the United States adult population with over 120,000 people living with the disease. Despite new and more effective treatments, multiple myeloma, unfortunately, remains largely incurable with relapse and disease progression still common. Dr. Ola Landgren Chief of the Myeloma Service at Memorial Sloan-Kettering Cancer Center and professor of medicine at Cornell Medical College discusses advances in the field of immunothera...
Annenberg Center for Health Sciences at Eisenhower

Meeting the Medical Needs of Patients with Ulcerative Colitis During the COVID-19 Pandemic

The COVID-19 pandemic is an unprecedented challenge for all healthcare systems worldwide. Gastroenterologists and clinicians who actively manage patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC), need to ensure they are taking steps to minimize the risk of infection for their patients. Russell D. Cohen, MD, shares his expert perspective as an author of the recently published AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the C...
Annenberg Center for Health Sciences at Eisenhower

Eosinophilia in Patients With Asthma: A Sign of Eosinophilic Granulomatosis With Polyangiitis (EGPA)

PART 1: Welcome to this overview of eosinophilic granulomatosis with polyangiitis with Michael Wechsler, MD. In this activity, Dr. Wechsler reviews the pathogenesis, diagnosis, prognosis, and treatment of EGPA. This presentation will help you recognize EGPA and differentiate it from other diagnoses and other small-vessel vasculitides, and develop treatment plans based on the patient’s prognosis and response to first-line treatments. PART 2: Welcome to this video question and answer inte...
Annenberg Center for Health Sciences at Eisenhower

Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma

STATEMENT OF NEED Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 2,488 cases are diagnosed in the United States annually (Paulson et al, 2018). The incidence of MCC has risen rapidly during the past few decades, which has been attributed in part to people living longer with increased sun exposure and weakened immune systems, a feature that suggests an infectious origin an...
i3 Health

New Data and Clinical Perspectives on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States. An estimated 191,930 new cases are diagnosed annually, and 33,330 people die from the disease (ACS, 2020). Most patients with metastatic hormone-sensitive prostate cancer (HSPC) present with relapse after local treatment, while approximately 5% of all prostate cancer patients present with de novo metastatic HSPC (Ng et al, 2020). The five-year overall survival rate for metastatic HSPC remains...
i3 Health

Metastatic Breast Cancer: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

STATEMENT OF NEED Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population (ACS, 2019). Although many women benefit from regular screening as well as earlier and improved treatment, approximately 6% present with metastatic disease, and up to 30% with no initial lymph node involvement eventually develop metastatic disease (Siegel et al, 2019; Mortensen et al, 2018). Women with MBC have...
i3 Health

Diagnosis, Treatment and Prevention Therapies in Primary Headache Disorders

ACTIVITY OVERVIEW Primary headache disorders are a major cause of disability and a common reason people seek medical care. However, distinguishing a primary from a secondary headache disorder, as well as among primary headache disorders, is often challenging. Focusing on cluster and migraine, Drs. Jessica Ailani and Stewart Tepper provide criteria and strategies to overcome this challenge in the office setting. Insight is also provided to help guide treatment with evidence-based medications a...
Annenberg Center for Health Sciences at Eisenhower

Keeping Pace With Evolving Treatment Paradigms in Advanced Renal Cell Carcinoma: The Nurse’s View

STATEMENT OF NEED Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at ...
i3 Health

Expert Guidance on New Advances in Renal Cell Carcinoma

STATEMENT OF NEED Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at ...
i3 Health

Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Metastatic Breast Cancer

STATEMENT OF NEED Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population (ACS, 2020). Although many women benefit from regular screening as well as earlier and improved treatment, approximately 6% present with metastatic disease, and up to 30% with no initial lymph node involvement eventually develop metastatic disease (Siegel et al, 2020; Mortensen et al, 2018). Women with metastat...
i3 Health

Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Advanced Soft Tissue Sarcoma

STATEMENT OF NEED Soft tissue sarcomas are a heterogeneous group of malignancies that arise primarily from the mesodermal tissues of the extremities, trunk and retroperitoneum, and head and neck. An estimated 13,130 new cases are diagnosed in the United States annually and 5,350 people die of the disease. Surgical resection is the mainstay of treatment for localized soft tissue sarcoma, with radiation and chemotherapy commonly used as adjuncts. However, nearly 50% of patients will experienc...
i3 Health

Navigating the Recent Rheumatoid Arthritis Guidelines to Achieve Disease Remission and Reduce Patient

Roy M. Fleischmann, MD, discusses the latest evidence for the management of patients with moderate-to-severe rheumatoid arthritis who do not achieve treatment goals with initial disease-modifying anti-rheumatic drug therapy. A key treatment principle emphasized by Dr. Fleischmann is using a treat-to-target approach guided by validated tools for assessing disease activity and patient-reported outcomes. Among the treatment options, Dr. Fleischmann highlights the pharmacology of the latest approv...
Annenberg Center for Health Sciences at Eisenhower

Navigating Advancements in Diagnosis & Treatment of Axial Spondyloarthritis

More than 80% of the population has significant back pain at some point in their life, with 30% of adults in the United States stating they have chronic low back pain at any given time; 5% of whom have inflammatory back pain. Axial spondyloarthritis (axSpA) affects almost 1.5% of patients with inflammatory back pain; however, the majority of individuals suffering with back pain are not being treated by a rheumatologist, which only exacerbates the challenge to diagnose those with axSpA. Dr....
Annenberg Center for Health Sciences at Eisenhower

Research Developments in Atopic Dermatitis

Welcome to this activity focusing on new research related to atopic dermatitis presented as posters at the 2020 virtual annual meetings of the American Academy of Dermatology and the American Academy of Allergy, Asthma, and Immunology. The posters focus on new data related to the use of advanced therapies for atopic dermatitis. Beyond discussing the methods and results of each poster, the faculty, Drs. Steven Feldman and Alan Fleischer, Jr., share their views on the implication of the trial re...
Annenberg Center for Health Sciences at Eisenhower

Immune Thrombocytopenia: Evolving Treatment Paradigms and Patient-Centered Care

STATEMENT OF NEED Immune thrombocytopenia is an acquired immune-mediated disorder defined as a peripheral blood platelet count
i3 Health

Defining Personalized Care Plans in Metastatic Colorectal Cancer

STATEMENT OF NEED Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages. Approximately 21% of patients present with m...
i3 Health

Tumor-induced Osteomalacia (TIO): Diagnosis and Management

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic condition commonly characterized by bone pain, muscle weakness and fractures. These tumors secrete excess fibroblast growth factor 23 (FGF23) which inhibits the sodium phosphate renal co-transporters and suppresses 1α hydroxylase activity, thereby decreasing renal reabsorption and increased urinary phosphate excretion. As a result, unexplainable hypophosphatemia with a variety of musculoskeletal abnormalities are the most common sympto...
CheckRare

Neuroendocrine Tumors (NETs) Research Highlights from ENDO 2020

Although the 2020 Endocrine Society’s annual meeting (ENDO 2020) did not take place as scheduled, abstracts, including new information and data on neuroendocrine tumors (NETs) were published. This CME activity highlights the latest information about NETs from ENDO 2020 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with these rare diseases.
CheckRare

Food Allergy: From Primary Prevention to Treatment and Intervention Online

This online offering includes 19 videos of lectures and panel discussions on the diagnosis and management, specific syndromes, treatment, and research and prevention of food allergy. The videos were recorded at a live course that took place at a live AAAAI course held in early September, 2019. The intent of the videos is to allow learners to increase their knowledge related to the diagnosis and management of food allergic patients. It highlights the latest evidence related to food allergie...
American Academy of Allergy, Asthma & Immunology

Conversations from the World of Allergy: Podcast Episodes for Credit

This podcast features interviews on a wide variety of allergy/immunology topics. It is our hope that the conversations provide evidence-based information that is useful to clinicians, researchers and patients, alike. Some episodes are available for CME credit. All podcast episodes are available at https://www.aaaai.org/professional-education-and-training/podcasts
American Academy of Allergy, Asthma & Immunology

Reducing Healthcare Disparities for PAH Patients

Very few studies have assessed the impact of healthcare disparities on PAH, despite the potential adverse impacts. One such study from Talwar et al reported that minority PAH patients may be at risk for worse outcomes due to lack of healthcare access, insurance gaps, and socioeconomic status. Dr. Victor Tapson, Director, Pulmonary Vascular Disease Research at Cedars-Sinai Medical Center, draws from his own experience of treating PAH patients and shares how increased awareness and education can...
ACHL

17th Bleeding and Thrombosing Diseases Conference and Workshop

This Mayo Clinic conference will provide reviews and updates about laboratory and clinical aspects of bleeding and thrombosing disorders. Informational presentations will be supplemented with panel discussions and case presentations, followed by time for participant questions.
Mayo Clinic Laboratories

Non-Malignant Hematology Conference

This conference will use didactic lectures and case studies, the overall objective of this program is to provide an update on interpretation and optimal application of standard and evolving test repertoire to diagnose non-malignant blood disorders. Combining the clinical and laboratory experience of our Mayo Clinic faculty, we will illustrate the practical application of testing algorithms derived from the Mayo Clinic practices, and how unnecessary, redundant, and costly laboratory tests can b...
Mayo Clinic Laboratories

Strategies for Successfully Diagnosing and Treating Tardive Dyskinesia: Enlisting the Help of Caregivers, Improving the Lives of Patients

At any given time, roughly 1 of every 4 patients taking antipsychotics experiences tardive dyskinesia (TD), a debilitating condition characterized by involuntary movements of the tongue, lips, face, trunk, and extremities. Fortunately, effective pharmacologic treatments for TD are now available. However, it can be challenging for clinicians to assess patients for TD, keep up to date on new agents, and create personalized treatment plans that facilitate long-term treatment success. In this acti...
CMEology

Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary. Faculty discussion will focus on: ...
ACHL

Hot Topics in Oncology – Focus on the Immune Checkpoint Inhibitors (ICIs)

The immune checkpoint inhibitors (ICIs) continue to break ground in a multitude of cancer types. With ever-evolving data and recommendations, oncology clinicians must keep pace with the latest ICI updates. This recorded CME-certified session tackles questions surrounding topics related to immune checkpoint inhibitors with discussion on: • Role of biomarkers with ICI selection and monitoring • Latest expanded ICI indications • Immune-related adverse events This session also featu...
ACHL

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map